Skip to main content

Table 2 The lung status of SARS survivors assessed by mMRC score, pulmonary function tests, and chest CT

From: Investigation of the impact of SARS-CoV infection on the immunologic status and lung function after 15 years

 

The severe group

The non-severe group

F/T

P

mMRC scorea

N = 22

N = 34

  

 0

5 (22.7%)

11 (32.4%)

4.785

0.310

 1

11 (50.0%)

12 (35.3%)

  

 2

3 (13.6%)

10 (29.4%)

  

 3

3 (13.6%)

1 (2.9%)

  

Pulmonary function parametersb

N = 21

N = 31

  

 FVC (L)

3.10 ± 0.59

3.52 ± 0.6

− 2.517

0.015

 FVC (%)

101.41 ± 14.52

104.69 ± 13.30

0.835

0.408

 FVC% < 80%

0

0

 FEV1(L)

2.48 ± 0.514

2.90 ± 0.453

3.313

0.003

 FEV1 (%)

95.21 ± 12.46

101.61 ± 12.66

1.604

0.108

 FEV1% < 80%

4 (19.0%)

0

6.397

0.011

 FEV1/FVC (%)

79.23 ± 4.35

82.64 ± 4.80

2.611

0.012

 FEV1/FVC < 70%

1 (4.8%)

0

1.505

0.220

 DLCO (mmol/min/KPa)

6.86 ± 1.31

7.18 ± 1.43

0.807

0.424

 DLCO (%)

84.01 ± 11.06

82.18 ± 12.42

− 0.563

0.576

 DLCO% < 80%

6 (28.6%)

13 (41.9%)

0.964

0.326

 TLC (L)

5.05 ± 0.87

5.39 ± 0.71

1.599

0.116

 TLC (%)

100.32 ± 10.83

103.93 ± 9.37

1.277

0.207

 TLC% < 80%

0

0

 RV/TLC (%)

38.69 ± 5.86

37.23 ± 5.77

− 0.889

0.378

 RV (%)

107.73 ± 13.66

111.70 ± 17.22

0.884

0.381

 RV% > 120%

6 (28.6%)

12 (38.7%)

0.569

0.451

 FEF25–75 (%)

65.95 ± 19.73

82.69 ± 20.36

2.946

0.005

 FEF25–75% < 65%

12 (57.1%)

7 (22.6%)

6.449

0.011

CT abnormalitiesc

N = 22

N = 33

  

 GGO

6 (27.3%)

2 (6.0%)

16.360

< 0.001

 Interstitial fibrosis

7 (31.8%)

0

  

 Others

5 (22.7%)

1 (3.0%)

  
  1. a, b, c, The number of SARS survivors undertaking different tests